Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2016 | 09-2016 | 06-2016 | 03-2016 | 12-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 15,362 | 16,059 | 18,003 | 22,356 | 25,846 |
| TOTAL | $15,794 | $16,112 | $18,242 | $22,781 | $26,400 |
| Non-Current Assets | |||||
| Intangibles | 1 | 3 | 5 | 7 | 8 |
| TOTAL | $1 | $3 | $5 | $7 | $8 |
| Total Assets | $15,795 | $16,115 | $18,247 | $22,788 | $26,408 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 910 | 652 | 932 | 1,311 | 448 |
| Accrued Expenses | 2,802 | 3,435 | 2,636 | 1,939 | 845 |
| TOTAL | $3,780 | $4,087 | $3,636 | $3,250 | $1,360 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $3,780 | $4,087 | $3,636 | $3,250 | $1,360 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 34,065 | 29,397 | 29,281 | 28,979 | 28,825 |
| Common Shares | 33 | 29 | 29 | 28 | 28 |
| Retained earnings | -163,701 | -158,524 | -152,887 | -147,060 | -140,049 |
| Other shareholders' equity | 8,962 | 8,347 | 7,681 | 7,623 | 7,565 |
| TOTAL | $12,015 | $12,028 | $14,611 | $19,538 | $25,048 |
| Total Liabilities And Equity | $15,795 | $16,115 | $18,247 | $22,788 | $26,408 |